Liquidia (LQDA) said Friday the US Food and Drug Administration approved Yutrepiatm for patients with pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease.
The approval was based on the findings of a phase 3 trial that evaluated the prostacyclin analog's effectiveness in facilitating better exercise ability, according to a statement. The candidate was recorded as safe and well-tolerated.
An argument on a motion filed by United Therapeutics (UTHR) for a restraining order and preliminary injunction to block Liquidia from launching Yutrepia was held on May 20. The motion is pending in court, the company said.
Shares were up 0.8% after resuming trade following a trade halt.
Price: 15.51, Change: -0.05, Percent Change: -0.32
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。